30-day FRN

Federal Register / Vol. 84, No. 207 / Friday, October 25, 2019 / Notices
Dated: October 21, 2019.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2019–23285 Filed 10–24–19; 8:45 am]

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIH Support for
Conferences and Scientific Meetings (Parent
R13 Clinical Trial Not Allowed).
Date: November 4–6, 2019.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892 (Virtual
Meeting).
Contact Person: Ellen S. Buczko, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
Room #3F30A, National Institutes of Health/
NIAID, 5601 Fishers Lane, MSC 9824,
Bethesda, MD 20892–9824, (240) 669–5028,
[email protected].
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: October 21, 2019.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
BILLING CODE 4140–01–P

VerDate Sep<11>2014

18:04 Oct 24, 2019

Jkt 250001

National Institutes of Health
National Institute on Aging; Notice of
Closed Meeting

BILLING CODE 4140–01–P

[FR Doc. 2019–23281 Filed 10–24–19; 8:45 am]

DEPARTMENT OF HEALTH AND
HUMAN SERVICES

Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Aging Special Emphasis Panel; SWAN.
Date: November 18, 2019.
Time: 11:00 a.m. to 1:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging,
Gateway Building, 7201 Wisconsin Avenue,
Bethesda, MD 20892 (Telephone Conference
Call).
Contact Person: Isis S. Mikhail, MD, MPH,
DrPH, Scientific Review Officer, Scientific
Review Branch, National Institute on Aging,
National Institutes of Health, Gateway
Building 2C212, 7201 Wisconsin Avenue,
Bethesda, MD 20892, Tel: 301–402–7704,
[email protected].
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS)
Dated: October 21, 2019.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2019–23290 Filed 10–24–19; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Submission for OMB Review; 30-Day
Comment Request; Summer Research
Internship Program (National Institute
on Drug Abuse)
AGENCY:

National Institutes of Health,

HHS.
ACTION:

Notice.

In compliance with the
Paperwork Reduction Act of 1995, the
National Institutes of Health (NIH) has
submitted to the Office of Management

SUMMARY:

PO 00000

Frm 00076

Fmt 4703

Sfmt 4703

57457

and Budget (OMB) a request for review
and approval of the information
collection listed below.
DATES: Comments regarding this
information collection are best assured
of having their full effect if received
within 30 days of the date of this
publication.
ADDRESSES: Written comments and/or
suggestions regarding the item(s)
contained in this notice, especially
regarding the estimated public burden
and associated response time, should be
directed to the: Office of Management
and Budget, Office of Regulatory Affairs,
[email protected] or by
fax to 202–395–6974, Attention: Desk
Officer for NIH.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the data collection plans and
instruments, contact: Dr. Albert Avila,
Director, National Institute on Drug
Abuse, Office of Diversity and Health
Disparity, Neuroscience Center,
Building 6001, Room 3106, Rockville,
Maryland 20852 or call non-toll-free
number (301) 496–8804 or Email your
request, including your address, to:
[email protected]. Formal requests
for additional plans and instruments
must be requested in writing.
SUPPLEMENTARY INFORMATION: This
proposed information collection was
previously published in the Federal
Register on March 12, 2019, page 8881
(84 FR 8881) and allowed 60 days for
public comment. No public comments
were received. The purpose of this
notice is to allow an additional 30 days
for public comment. The National
Institute on Drug Abuse (NIDA),
National Institutes of Health, may not
conduct or sponsor, and the respondent
is not required to respond to, an
information collection that has been
extended, revised, or implemented on or
after October 1, 1995, unless it displays
a currently valid OMB control number.
In compliance with Section
3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, the National
Institutes of Health (NIH) has submitted
to the Office of Management and Budget
(OMB) a request for review and
approval of the information collection
listed below.
Proposed Collection Title: NIDA
Summer Research Internship Program,
0925–0738, Expiration 03/31/2019,
REINSTATEMENT WITH CHANGE,
National Institute on Drug Abuse
(NIDA), National Institutes of Health
(NIH).
Need and Use of Information
Collection: The purpose of the proposed
information is for the selection of

E:\FR\FM\25OCN1.SGM

25OCN1

57458

Federal Register / Vol. 84, No. 207 / Friday, October 25, 2019 / Notices

interns for the continuing NIDA
Summer Research Internship Program.
This request is to allow NIDA to collect
information from applicants in order to
meet the goals of the program and IC
mission. Applicant eligibility for this
program was 17 years, but is now open
to those 18 and over in the year of
application per NIH policy document
2019 High School Summer Internship
Program (HS–SIP) Policy. NIDA will

which applicants will be selected for
internships. In each case, completing
the application is voluntary, but in
order to receive due consideration, the
prospective applicant must complete all
fields required by the program.
OMB approval is requested for 3
years. There are no costs to respondents
other than their time. The total
estimated annualized burden hours are
250.

request clearance for any additional
forms should new programs be
introduced in the future. The
information ensures that students
applying to this program meet basic
eligibility requirements; indicates their
interest in substance abuse research,
future career goals, and, if selected for
the program, what research they prefer
to conduct. The information also
enables decision-making regarding

ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents

Number of
responses per
respondent

Average
burden per
response
(in hours)

Estimated
total annual
burden hours

Form

Type of respondent

Summer Internship ............................

Individuals-household .......................

250

1

1

250

Total ...........................................

...........................................................

........................

250

........................

250

Dated: October 16, 2019.
Lanette A. Palmquist,
Project Clearance Liaison, National Institute
on Drug Abuse, National Institutes of Health.
[FR Doc. 2019–23283 Filed 10–24–19; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Center for Advancing
Translational Sciences; Notice of
Workshop
Notice is hereby given of a workshop
convened by the National Center for
Advancing Translational Sciences Cures
Acceleration Network Review Board.
Purpose
The National Center for Advancing
Translational Sciences is hosting the
Cures Acceleration Network Review
Board (CAN RB) Workshop: The CAN
RB advises and provides
recommendations to the NCATS
Director with respect to significant
barriers to successful translation of basic
science into clinical application. In
support of this mandate, the CAN RB
will co-host this public workshop to
discuss challenges around finding new
uses for drugs that are already on the
market but lack commercial and
regulatory incentives for research and
development.
The Workshop is being co-sponsored
by the NCATS Cures Acceleration
Network Review Board, NCATS Drug
Development Partnership Programs,
Food and Drug Administration, and
Reagan-Udall Foundation for the FDA.

VerDate Sep<11>2014

18:04 Oct 24, 2019

Jkt 250001

Name of Committee: National Center
for Advancing Translational Sciences
Cures Acceleration Network Review
Board.
Type of Meeting: Repurposing OffPatent Drugs: Research & Regulatory
Challenges.
Date: December 5–6, 2019.
Time: 7:30 a.m. to 5:00 p.m., Eastern
Standard Time (EST).
Agenda: The Workshop will assess
challenges around finding new uses for
drugs that are already on the market but
lack commercial and regulatory
incentives for research and
development. On December 5, we will
map out the challenges to repurposing
off-patent drugs. On December 6, we
will host interactive work sessions
focused on capturing possible solutions.
Place: Hilton Washington DC/
Rockville Hotel & Executive Meeting
Center, 1750 Rockville Pike, Rockville,
MD 20852.
Cost: The meeting is free and open to
the public.
Registration: Registration is required.
Using the link below, attendees can
register by December 2, 2019, 5:00 p.m.
EST. Early registration is recommended
due to limited seating. https://
reaganudall.salsalabs.org/
repurposingoffpatentdrugsworkshop/
index.html.
Access: Twinbrook Metro Station
(Red Line).
Contact Person: Bobbie Ann Mount,
Ph.D., Program Officer, Drug
Development Partnership Programs,
Office of the Director, National Center
for Advancing Translational Sciences,
National Institutes of Health.
Telephone: 301.435.0824, Email:
[email protected].
Disability Accommodations:
Individuals whose full participation in

PO 00000

Frm 00077

Fmt 4703

Sfmt 9990

the workshop will require special
accommodations (e.g., sign language, or
interpreting services, etc.) must submit
a request to the Contact Person listed on
the notice at least ten (10) business days
prior to the meeting. Such requests
should include a detailed description of
the accommodation needed and a way
to contact the requester if more
information is needed to fill the request.
Special requests should be made as
early as possible. Last minute requests
may be made but may not be possible
to accommodate.
Security: Visitors will be asked to
show one form of identification (for
example, a government-issued photo ID,
driver’s license, or passport) and to state
the purpose of their visit. Also, as a part
of security procedures, attendees should
be prepared to present a photo ID at the
meeting registration desk during the
check-in process. Pre-registration is
recommended. Seating will be limited
to the room capacity and seats will be
on a first come, first serve basis, with
expedited check-in for those who are
pre-registered.
Meeting schedule subject to change.
For more information, visit: https://
reaganudall.salsalabs.org/
repurposingoffpatentdrugsworkshop/
index.html.
Dated: October 21, 2019.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2019–23280 Filed 10–24–19; 8:45 am]
BILLING CODE 4140–01–P

E:\FR\FM\25OCN1.SGM

25OCN1